Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat
by Kinjel Shah
Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.
Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.
Momenta Says District of Delaware Invalidates Teva's MS Drug
by Zacks Equity Research
Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .
Mylan (MYL) Gets Favorable Verdict for Copaxone in the US
by Zacks Equity Research
Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.
Allergan (AGN) Avycaz Label to Include New Phase III Data
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
by Zacks Equity Research
We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.
New Strong Sell Stocks for January 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.
Stock Market News for January 09, 2017
by Zacks Equity Research
Benchmarks posted modest gains on Friday following a solid December U.S. jobs report
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.
Teva Falls on Disappointing 2017 Sales & Earnings Guidance
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.
Here's Why Teva Pharmaceuticals is Plunging Today
by Madeleine Johnson
On Friday, shares of Teva Pharmaceuticals Industries (TEVA) are plunging, down almost 7.7% in late-afternoon trading after the company announced weaker-than-expected 2017 guidance.
Teva Settles Foreign Bribery Charges with U.S. Government
by Zacks Equity Research
Teva (TEVA) announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act.
Allergan to Buy LifeCell to Boost Regenerative Medicine Suite
by Zacks Equity Research
Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.
Mylan (MYL) Launches Authorized Generic EpiPen at $300
by Zacks Equity Research
Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.
20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing
by Arpita Dutt
The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).
Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe
by Arpita Dutt
Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.
Teva Copaxone EU Label to Omit Pregnancy Contraindication
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.